Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Perspective Therapeutics Inc. (CATX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CATX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 292.6% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 145.14M USD | Price to earnings Ratio - | 1Y Target Price 15.18 |
Price to earnings Ratio - | 1Y Target Price 15.18 | ||
Volume (30-day avg) 612258 | Beta 1.26 | 52 Weeks Range 1.90 - 19.10 | Updated Date 04/2/2025 |
52 Weeks Range 1.90 - 19.10 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.22 |
Earnings Date
Report Date 2025-03-27 | When - | Estimate -0.256 | Actual -0.2433 |
Profitability
Profit Margin - | Operating Margin (TTM) -8929.49% |
Management Effectiveness
Return on Assets (TTM) -19.02% | Return on Equity (TTM) -42.82% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -77712392 | Price to Sales(TTM) 99.82 |
Enterprise Value -77712392 | Price to Sales(TTM) 99.82 | ||
Enterprise Value to Revenue 68.73 | Enterprise Value to EBITDA -21.91 | Shares Outstanding 74051800 | Shares Floating 54562137 |
Shares Outstanding 74051800 | Shares Floating 54562137 | ||
Percent Insiders 18.63 | Percent Institutions 64.34 |
Analyst Ratings
Rating 4.7 | Target Price 16.15 | Buy 1 | Strong Buy 8 |
Buy 1 | Strong Buy 8 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Perspective Therapeutics Inc.
Company Overview
History and Background
Perspective Therapeutics Inc. (formerly known as Isoray, Inc.) was founded in 1983. Initially focused on brachytherapy using Cesium-131, the company has transitioned to focus on radiopharmaceuticals for cancer therapy. Significant milestones include the development of Cesium-131 seeds and the acquisition of exclusive worldwide rights to astatine-211-based radiopharmaceuticals. The company has evolved from focusing on a specific isotope in brachytherapy to a broad pipeline of targeted alpha therapies.
Core Business Areas
- Radiopharmaceutical Therapy: Perspective Therapeutics develops and commercializes radiopharmaceuticals, focusing on alpha particle therapy for various cancers. They leverage the unique properties of Astatine-211 to deliver targeted radiation to cancer cells.
Leadership and Structure
The leadership team consists of key executives focused on clinical development, regulatory affairs, and commercial strategy. Organizational structure involves departments dedicated to research and development, manufacturing, clinical trials, and business development. The board of directors provides oversight and guidance.
Top Products and Market Share
Key Offerings
- Astatine-211 based radiopharmaceuticals: Perspective Therapeutics is developing a pipeline of Astatine-211 based radiopharmaceuticals targeting various cancers, including lymphoma, melanoma, and neuroendocrine tumors. Since these products are in clinical development stages, market share is not yet available. Competitors in the radiopharmaceutical therapy space include Novartis (Lutathera), Bayer (Xofigo), and Telix Pharmaceuticals.
Market Dynamics
Industry Overview
The radiopharmaceutical market is experiencing significant growth driven by advances in targeted therapies and increasing prevalence of cancer. There's a shift towards precision medicine and personalized cancer treatments, with radiopharmaceuticals playing a crucial role.
Positioning
Perspective Therapeutics is positioned as a developer of novel alpha-emitting radiopharmaceuticals. Its competitive advantage lies in the use of Astatine-211, which offers potential benefits in terms of therapeutic efficacy and safety compared to other radioisotopes.
Total Addressable Market (TAM)
The overall radiopharmaceutical market is estimated to reach billions of dollars. Perspective Therapeutics is positioned to capture a portion of this TAM through its targeted alpha therapy pipeline. Specific TAM for each cancer indication varies. For example, the market for neuroendocrine tumor therapies is projected to reach $2 billion by 2028. Perspective Therapeutics is working towards capturing market share in segments where targeted alpha therapy has a significant advantage.
Upturn SWOT Analysis
Strengths
- Novel Astatine-211 based radiopharmaceutical technology
- Targeted alpha therapy platform
- Experienced management team
- Intellectual property protection
Weaknesses
- Limited commercialized products
- Dependence on successful clinical trial outcomes
- Manufacturing complexity of Astatine-211
- Relatively small market capitalization
Opportunities
- Expanding pipeline of radiopharmaceuticals
- Strategic partnerships and collaborations
- Regulatory approvals for key products
- Increasing demand for targeted cancer therapies
Threats
- Competition from established radiopharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- NVS
- BAYRY
- TLX
Competitive Landscape
Perspective Therapeutics faces competition from established radiopharmaceutical companies with approved products. Its advantage lies in the potential of its novel Astatine-211 technology.
Major Acquisitions
iTheranostics, Inc.
- Year: 2022
- Acquisition Price (USD millions): 4.5
- Strategic Rationale: Acquired iTheranostics, Inc. to secure exclusive worldwide rights to a portfolio of intellectual property and technology related to the use of Astatine-211 (At-211) in cancer therapy.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by pipeline development and preclinical/clinical progress rather than revenue generation.
Future Projections: Future growth is contingent on successful clinical trials and regulatory approvals. Analyst estimates vary depending on the perceived likelihood of success for key pipeline candidates.
Recent Initiatives: Recent initiatives include advancing clinical trials for lead radiopharmaceutical candidates, expanding the pipeline through strategic in-licensing, and strengthening the manufacturing capabilities.
Summary
Perspective Therapeutics is a development-stage company focusing on novel radiopharmaceuticals, particularly those based on Astatine-211. Its strength lies in its targeted alpha therapy platform and the potential of Astatine-211. The company needs to successfully navigate clinical trials and regulatory hurdles. Success depends on demonstrating the efficacy and safety of its radiopharmaceutical candidates. Investors should monitor clinical trial results and regulatory milestones carefully.
Similar Companies
NVS
Novartis AG ADR
NVS
Novartis AG ADR
SNY
Sanofi ADR
SNY
Sanofi ADR
TLX
Telix Pharmaceuticals Limited
TLX
Telix Pharmaceuticals Limited
Sources and Disclaimers
Data Sources:
- Company website, SEC filings, press releases, analyst reports, market research reports.
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Perspective Therapeutics Inc.
Exchange NYSE MKT | Headquaters Seattle, WA, United States | ||
IPO Launch date 2005-11-10 | CEO & Director Mr. Johan M. Spoor | ||
Sector Healthcare | Industry Medical Devices | Full time employees 138 | |
Full time employees 138 | |||
Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.